Targovax TG01 immunotherapy reaches phase IIA in operable pancreatic cancer

In the TG01 clinical trial, patients start treatment 1-8 weeks after surgery of pancreatic cancer.

A patent application with priority 2013 provides the base for expanding pipeline to broader indications. Pipeline drug candidates will cover 99% of the RAS-positive cancers, the cancer medicine TG02 will initially be developed for colorectal and lunc (NSCLC) cancers.

Targovax’s RAS specific immunotherapy triggers both cytotoxic and helper T-cell responses, educating the patients’ immune system to recognize and kill the cancer cells.

Press release (English, Norwegian), Business Wire

Clinical study: (in Norwegian, OUS Radiumhospitalet), (in English, Nordic NECT)